查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403359

到 2030 年骨髓增生性疾病市场预测：按类型、诊断和筛检方法、治疗方案、最终用户和地区进行的全球分析

Myeloproliferative Disorders Market Forecasts to 2030 - Global Analysis By Type, Diagnosis and Screening Methods, Treatment Option, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球骨髓增生性疾病市场在预测期内将以 4.4% 的复合年增长率成长。

一组称为骨髓增殖性疾病 (MPD) 的罕见血液疾病的定义是骨髓中成熟血球的过度生成。红血球、白血球和血小板都是受这种异常生长影响的细胞。定期监测对于疾病管理和预防急性白血病的潜在进展至关重要。治疗的目标是尽量减少症状、减少併发症并阻止症状恶化。

根据国际癌症研究机构提供的2021年资料，2020年欧洲地区癌症患者人数为479万人，预计2040年将增加至607万人。

对疾病意识的需求不断增长

随着公众和医疗保健专业人员对这些疾病的认识不断增强，骨髓增生性疾病 (MPD) 也随之被发现。教育、医疗保健措施和宣传宣传活动对于传播意识至关重要，对创新治疗方法和疗法的需求也相应增加。透过这种方式，提高对该疾病的认识，鼓励早期疗育并提高受影响者的护理标准，从而扩大市场规模，从而对 MPD 产生积极影响。

昂贵的治疗费用

政府和保险公司可能会发现很难承担为骨髓增生性疾病（MPD）提供广泛且昂贵的治疗的财务负担。药物、治疗和可能的干细胞移植的高昂成本给患者和医疗保健系统带来了经济负担，这可能会影响整体健康结果。因此，治疗费用的急剧上升是骨髓增生性疾病（MPD）市场的主要抑制因素。

诊断技术的进步

分子谱分析、诊断影像和基因检测的新发展正在提高 MPD 诊断的准确性和有效性。诊断技术的改进也有助于及时干预，从而减缓疾病的进展及其影响。此外，诊断技术的持续研发表明我们致力于优化骨髓增生性疾病的资讯并协助医疗保健专业人员做出明智的决策，从而逐步支持市场的扩张。

药物开发中的遗传复杂性

药物开发工作在确定适用于 MPD 遗传频谱的通用分子标靶方面面临障碍。这是因为不同的亚型，例如JAK2基因、CALR基因和MPL基因的突变，需要不同的治疗方法并具有不同的疾病表型。此外，根治性治疗方法的开发和对复杂分子机制的持续研究正在减少，这阻碍了疾病领域的扩展。

COVID-19 的影响

这场大流行扰乱了常规医疗服务，导致许多 MPD 患者的诊断和开始治疗被延误，包括真性红血球增多症、原发性血小板增多症和骨髓纤维化等疾病，这些疾病削弱了免疫系统。并增加感染疾病的可能性。因此，由于这些综合因素，骨髓增生性疾病市场面临挑战，影响患者治疗和整体市场扩张。

真性红血球增多症（PV）领域预计在预测期内将是最大的。

真性红血球增多症（PV）领域估计占最大份额。 PV 的特征是骨髓损伤，可导致血液黏度增加、凝血和心血管问题。正在进行的研究的目标是创造新的治疗方法改善真性红血球增多症患者的生活、控制症状并降低血栓症的风险。因此，骨髓增生性疾病市场的特征是控制疾病和改善患者整体健康之间的微妙平衡，这推动了该领域的扩张。

骨髓切片检查领域预计在预测期内复合年增长率最高

骨髓切片检查领域预计在预测期内复合年增长率最高。骨髓切片检查是确定细胞生成异常和评估骨髓健康状况的重要诊断过程。它对于了解基因突变、细胞型态和骨髓增生性疾病的病程极为重要。此外，研究人员正在进行实验以改进切片检查方法并更好地利用分子见解。这提高了诊断效用，并有助于为这些疾病制定更好的治疗计划，从而推动该细分市场的成长。

比最大的地区

由于政府和医疗机构合作提高意识、改进诊断技术并确保获得尖端治疗方法，亚太地区在预测期内占据了最大的市场占有率。该地区的主要企业和主要国家，包括中国、日本和印度，专注于 MPD 创新治疗的研发活动激增。这导致了标靶治疗和干细胞移植等先进治疗方法的引入，进一步促进了该地区的成长。

复合年增长率最高的地区：

由于分子测试和基因分析等先进的诊断工具能够实现准确的疾病识别，预计北美在预测期内将呈现最高的复合年增长率。巨量资料分析和人工智慧的这些发展支持了对 MPD 和客製化治疗策略的更全面的了解。此外，Janus 激酶 (JAK) 抑制剂等标靶治疗可提高治疗效果，同时最大限度地减少副作用，因此受到关注，从而推动了该地区的扩张。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球骨髓增生性疾病市场：依类型

  • 真性多血症
  • 慢性骨髓性白血病（CML）
  • 原发性骨髓纤维化
  • 原发性血小板增多症
  • 其他类型

第六章全球骨髓增生性疾病市场：依诊断及筛检方法

  • 骨髓切片检查
  • 验血
  • 基因检测

第七章全球骨髓增生性疾病市场：依治疗方案分类

  • 骨髓移植
  • 治疗程序
  • 支持性护理
  • 药品
  • 化疗
  • 其他治疗选择

第八章全球骨髓增生性疾病市场：依最终用户分类

  • 製药公司
  • 研究机构
  • 医院和诊所
  • 其他最终用户

第九章全球骨髓增生性疾病市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Novartis AG
  • Teva Pharmaceutical Industries
  • AbbVie
  • Bristol Myers Squibb（BMS）
  • Roche
  • Incyte Corporation
  • Gilead Sciences
  • MP Biomedicals
  • Mylan
  • Roxall Medizin
  • AOP Orphan Pharmaceuticals AG
  • CTI BioPharma Corp
  • Promedior, Inc.
  • Celgene
Product Code: SMRC24584

According to Stratistics MRC, the Global Myeloproliferative Disorders Market is growing at a CAGR of 4.4% during the forecast period. A class of uncommon blood diseases known as myeloproliferative disorders (MPDs) is defined by the bone marrow's overproduction of mature blood cells. Red blood cells, white blood cells, and platelets are among the cells that are impacted by this aberrant proliferation. Regular monitoring is crucial for disease management and to prevent potential progression to acute leukemia. The goals of management are to minimize symptoms, cut down on complications, and stop the condition from getting worse.

According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.

Market Dynamics:

Driver:

Rising demand in disease awareness

Myeloproliferative Disorders (MPDs) among the general public and healthcare professionals are detected by improving recognition of these conditions. Campaigns for education, healthcare initiatives, and advocacy are essential in spreading awareness and there is a corresponding increase in demand for innovative treatments and therapies. Thus, all things considered, increased awareness of the disease has a positive impact on the MPD by encouraging early intervention and enhancing the standard of care for those who are affected which is driving the market size.

Restraint:

High cost treatment

Governments and insurance companies might find it difficult to handle the financial strain of offering extensive and expensive treatments for myeloproliferative disorder (MPD). Patients and healthcare systems bear a financial burden due to the high costs of medications, therapies, and possible stem cell transplants potentially impacting their overall health outcomes. Therefore, the high cost of treatment serves as a significant restraint in the myeloproliferative disorder (MPD) market.

Opportunity:

Technological advancements in diagnosis

New developments in molecular profiling, imaging, and genetic testing improve the precision and efficacy of MPD diagnosis. Improved diagnostic skills also make it easier to intervene quickly, which slows the course of the illness and its consequences. In addition, continuous research and development in diagnostic technologies demonstrates a dedication in optimizing the diagnosis of myeloproliferative disorders, assisting medical professionals in making well-informed decisions, and therefore gradually driving market expansion.

Threat:

Genetic complexities in drug development

Drug development efforts face obstacles in identifying common molecular targets applicable across the genetic spectrum of MPDs. This complexity makes it challenging to develop universal targeted therapies, as each subtype may require a distinct approach including mutations in JAK2, CALR, and MPL genes, leading to varied disease phenotypes. In addition, the development of curative therapies and ongoing research to intricate molecular mechanisms are decreased thereby hampering the segment expansion.

COVID-19 Impact

The pandemic has disrupted routine healthcare services, leading to delayed diagnoses and treatment initiation for many MPD patients, including conditions like polycythemia vera, essential thrombocythemia, and myelofibrosis, face heightened risks due to compromised immune systems and increased susceptibility to infections. Therefore, the market for myeloproliferative disorders faced difficulties as a result of these combined factors, which have an impact on patient care and market expansion overall.

The polycythemia vera (PV) segment is expected to be the largest during the forecast period

The Polycythemia Vera (PV) segment is estimated to hold the largest share. PV is characterized by a disorder of the bone marrow that can cause high blood viscosity, clotting, and cardiovascular problems. The goal of ongoing research is to create novel therapies that will help PV patients live better, manage their symptoms, and lower their risk of thrombosis. Thus, the myeloproliferative disorders market is characterized by a delicate balance between disease control and improving patients' overall well-being which is driving this segment expansion.

The bone marrow biopsy segment is expected to have the highest CAGR during the forecast period

The bone marrow biopsy segment is anticipated to have highest CAGR during the forecast period. It is a diagnostic process that is essential for determining abnormalities in cell production and evaluating the health of the bone marrow. They are crucial for learning about genetic mutations, cell morphology, and the course of myeloproliferative disorders. In addition, researchers are conducting experiments to improve biopsy methods and make better use of molecular insights, which will increase their diagnostic utility and help in developing better treatment plans for these conditions which are boosting this segment growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to governments and healthcare organizations which work together in raising awareness, advance diagnostic skills, and guarantee access to cutting-edge treatments. Key players and key countries in the region, including China, Japan, and India, have witnessed a surge in research and development activities focused on innovative therapies for MPDs. Therefore, this has resulted in introducing advanced treatment options, including targeted therapies and stem cell transplantation which further propel the growth of the region.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to sophisticated diagnostic tools that allow for accurate disease identification, like molecular testing and genetic profiling. These developments in big data analytics and artificial intelligence support more comprehensive knowledge of MPDs and customized treatment strategies. Moreover, people are turning to targeted therapies, such as Janus kinase (JAK) inhibitors, which increase treatment efficacy while minimizing side effects, which are driving the region's expansion.

Key players in the market:

Some of the key players in the Myeloproliferative Disorders Market include Novartis AG, Teva Pharmaceutical Industries, AbbVie, Bristol Myers Squibb (BMS), Roche, Incyte Corporation, Gilead Sciences, MP Biomedicals, Mylan, Roxall Medizin, AOP Orphan Pharmaceuticals AG, CTI BioPharma Corp, Promedior, Inc. and Celgene.

Key Developments:

In October 2023, Allergan Aesthetics, an AbbVie company announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines.

In September 2023, Ionis Pharmaceuticals, Inc. announced that it has entered an agreement with Roche for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD).

In August 2023, Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.

In July 2023, DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON™) platform, announced that it has been acquired by Novartis.

Types Covered:

  • Polycythemia Vera
  • Chronic Myeloid Leukemia (CML)
  • Primary Myelofibrosis
  • Essential Thrombocythemia
  • Other Types

Diagnosis and Screening Methods Covered:

  • Bone Marrow Biopsy
  • Blood Tests
  • Genetic Testing

Treatment Options Covered:

  • Bone Marrow Transplant
  • Therapeutic Procedures
  • Supportive Care
  • Medications
  • Chemotherapy
  • Other Treatment Options

End Users Covered:

  • Pharmaceutical Companies
  • Research Institutions
  • Hospitals and Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myeloproliferative Disorders Market, By Type

  • 5.1 Introduction
  • 5.2 Polycythemia Vera
  • 5.3 Chronic Myeloid Leukemia (CML)
  • 5.4 Primary Myelofibrosis
  • 5.5 Essential Thrombocythemia
  • 5.6 Other Types

6 Global Myeloproliferative Disorders Market, By Diagnosis and Screening Methods

  • 6.1 Introduction
  • 6.2 Bone Marrow Biopsy
  • 6.3 Blood Tests
  • 6.4 Genetic Testing

7 Global Myeloproliferative Disorders Market, By Treatment Option

  • 7.1 Introduction
  • 7.2 Bone Marrow Transplant
  • 7.3 Therapeutic Procedures
  • 7.4 Supportive Care
  • 7.5 Medications
  • 7.6 Chemotherapy
  • 7.7 Other Treatment Options

8 Global Myeloproliferative Disorders Market, By End Users

  • 8.1 Introduction
  • 8.2 Pharmaceutical Companies
  • 8.3 Research Institutions
  • 8.4 Hospitals and Clinics
  • 8.5 Other End Users

9 Global Myeloproliferative Disorders Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novartis AG
  • 11.2 Teva Pharmaceutical Industries
  • 11.3 AbbVie
  • 11.4 Bristol Myers Squibb (BMS)
  • 11.5 Roche
  • 11.6 Incyte Corporation
  • 11.7 Gilead Sciences
  • 11.8 MP Biomedicals
  • 11.9 Mylan
  • 11.10 Roxall Medizin
  • 11.11 AOP Orphan Pharmaceuticals AG
  • 11.12 CTI BioPharma Corp
  • 11.13 Promedior, Inc.
  • 11.14 Celgene

List of Tables

  • Table 1 Global Myeloproliferative Disorders Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 4 Global Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 5 Global Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 6 Global Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 7 Global Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 9 Global Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 10 Global Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 11 Global Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 12 Global Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 13 Global Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 14 Global Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 15 Global Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 16 Global Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 17 Global Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 18 Global Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 19 Global Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 20 Global Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 21 Global Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 22 Global Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 23 Global Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 27 North America Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 28 North America Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 29 North America Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 30 North America Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 31 North America Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 32 North America Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 33 North America Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 34 North America Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 35 North America Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 36 North America Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 37 North America Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 38 North America Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 39 North America Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 40 North America Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 41 North America Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 42 North America Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 43 North America Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 44 North America Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 45 North America Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 46 North America Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 50 Europe Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 51 Europe Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 52 Europe Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 53 Europe Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 54 Europe Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 55 Europe Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 56 Europe Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 57 Europe Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 58 Europe Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 59 Europe Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 60 Europe Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 61 Europe Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 62 Europe Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 63 Europe Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 64 Europe Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 65 Europe Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 66 Europe Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 67 Europe Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 68 Europe Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 69 Europe Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 73 Asia Pacific Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 74 Asia Pacific Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 75 Asia Pacific Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 76 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 77 Asia Pacific Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 78 Asia Pacific Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 79 Asia Pacific Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 80 Asia Pacific Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 81 Asia Pacific Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 82 Asia Pacific Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 83 Asia Pacific Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 84 Asia Pacific Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 85 Asia Pacific Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 86 Asia Pacific Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 87 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 88 Asia Pacific Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 89 Asia Pacific Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 90 Asia Pacific Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 91 Asia Pacific Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 92 Asia Pacific Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 96 South America Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 97 South America Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 98 South America Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 99 South America Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 100 South America Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 101 South America Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 102 South America Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 103 South America Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 104 South America Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 105 South America Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 106 South America Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 107 South America Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 108 South America Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 109 South America Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 110 South America Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 111 South America Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 112 South America Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 113 South America Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 114 South America Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 115 South America Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
  • Table 119 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Chronic Myeloid Leukemia (CML) (2021-2030) ($MN)
  • Table 120 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Primary Myelofibrosis (2021-2030) ($MN)
  • Table 121 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Essential Thrombocythemia (2021-2030) ($MN)
  • Table 122 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 123 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Diagnosis and Screening Methods (2021-2030) ($MN)
  • Table 124 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Bone Marrow Biopsy (2021-2030) ($MN)
  • Table 125 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 126 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 127 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Treatment Option (2021-2030) ($MN)
  • Table 128 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Bone Marrow Transplant (2021-2030) ($MN)
  • Table 129 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Therapeutic Procedures (2021-2030) ($MN)
  • Table 130 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Supportive Care (2021-2030) ($MN)
  • Table 131 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Medications (2021-2030) ($MN)
  • Table 132 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 133 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other Treatment Options (2021-2030) ($MN)
  • Table 134 Middle East & Africa Myeloproliferative Disorders Market Outlook, By End Users (2021-2030) ($MN)
  • Table 135 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 136 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 137 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 138 Middle East & Africa Myeloproliferative Disorders Market Outlook, By Other End Users (2021-2030) ($MN)